Bonnie Kultgen
Nurse Practitioner · Yakima, WANPI 1417967548
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 437 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 437 payments — averaging $26.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$1K
- GSK$878
- Pfizer$817
- Bayer$801
- Abbott$713
- plus $5K from 31 others
What the payments were for
- Food & beverage$11,365100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 54 | $2,180 |
| AbbVie | 59 | $1,246 |
| GSK | 27 | $878 |
| Pfizer | 42 | $817 |
| Bayer | 33 | $801 |
| Abbott | 27 | $713 |
| Boehringer Ingelheim | 25 | $627 |
| Novo Nordisk | 26 | $542 |
| Johnson & Johnson | 13 | $391 |
| Sumitomo Pharma America, Inc. | 13 | $316 |
| Phathom Pharmaceuticals, Inc. | 13 | $310 |
| Amgen | 15 | $283 |
| Lilly USA, LLC | 10 | $253 |
| Astellas Pharma US Inc | 5 | $204 |
| Teva Pharmaceuticals USA, Inc. | 2 | $199 |
| Mylan Specialty L.p. | 9 | $187 |
| Daiichi Sankyo Inc. | 6 | $157 |
| Novartis | 7 | $139 |
| Sanofi-aventis U.S. LLC | 6 | $136 |
| Eisai Inc. | 1 | $125 |
| Sunovion Pharmaceuticals Inc. | 6 | $120 |
| Viatris Specialty LLC | 5 | $106 |
| Esperion Therapeutics, Inc. | 4 | $82 |
| Kowa Pharmaceuticals America, Inc. | 5 | $73 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $67 |
| Xeris Pharmaceuticals, Inc. | 3 | $66 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| Harmony Biosciences LLC | 2 | $52 |
| Insmed, Inc. | 3 | $52 |
| Exact Sciences | 3 | $51 |
| Biogen | 1 | $28 |
| Bardy Diagnostics, Inc. | 1 | $26 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Seqirus USA Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,373 in reported general payments places this provider in the 95th percentile of 2,466 nurse practitioner providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 14 | $120,409 |
| OzempicSemaglutide | 101 | $107,901 |
| FarxigaDapagliflozin Propanediol | 121 | $103,892 |
| EliquisApixaban | 66 | $63,827 |
| MounjaroTirzepatide | 52 | $60,302 |
| TrulicityDulaglutide | 37 | $47,340 |
| JardianceEmpagliflozin | 47 | $45,173 |
| KerendiaFinerenone | 30 | $22,081 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $11,685 |
| Repatha SureclickEvolocumab | 14 | $7,548 |
| Potassium Chloride | 144 | $4,338 |
| Rosuvastatin Calcium | 249 | $3,997 |
| Levothyroxine Sodium | 318 | $3,687 |
| Irbesartan | 156 | $2,723 |
| Liothyronine Sodium | 100 | $2,597 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $542 | $107,901101 claims |
| Lilly USA, LLCMounjaro, Trulicity | $253 | $107,64289 claims |
| AstraZenecaFarxiga | $2,180 | $103,892121 claims |
| PfizerEliquis | $817 | $63,82766 claims |
| Boehringer IngelheimJardiance | $627 | $45,17347 claims |
| BayerKerendia | $801 | $22,08130 claims |
| AbbVieSynthroid | $1,246 | $1,18222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,466 nurse practitioner providers in Washington.
Other nurse practitioner in Yakima
- Olga VoloshinaSeattle$279K
- Sandra ChristensenSeattle$244K
- Felicia ForrestLynnwood$206K
- Amaris MurphyBellevue$146K
- Sonia GlennieSeattle$78K
- Megan WildesTacoma$72K
- Kate KennedyBellevue$63K
- Vicki HainesPasco$57K
- Jessica ArmitageSumner$46K
- Lia Duque Estrada de BarrosSeattle$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.